Literature DB >> 17367665

Effect of obstruction on longitudinal left ventricular shortening in hypertrophic cardiomyopathy.

Ivan Barac1, Shrikanth Upadya, Robert Pilchik, Glenda Winson, Michael Passick, Farooq A Chaudhry, Mark V Sherrid.   

Abstract

OBJECTIVES: We investigated the cause of the midsystolic drop (MSD) in left ventricular (LV) ejection velocities that are observed with hypertrophic cardiomyopathy (HCM) and severe obstruction.
BACKGROUND: Dynamic obstruction is an important determinant of symptoms and adverse outcome. The MSD in velocity and flow occurs in patients with gradients >60 mm Hg. The nadir velocity in the LV occurs simultaneously with peak gradient.
METHODS: We studied 36 patients with obstructive HCM and an MSD and compared them with 15 patients with HCM and no obstruction and with 25 age-matched normal control subjects. We measured LV ejection velocity proximal and distal to LV obstruction as well as tissue Doppler velocities and time intervals.
RESULTS: The duration of contraction of both the septum and lateral wall is shorter in obstructed patients with the MSD than in nonobstructed HCM patients: septal contraction 203 +/- 68 ms vs. 271 +/- 41 ms (p < 0.001). Parallel reduction in the length of shortening was noted: 1.2 +/- 0.6 cm vs. 1.9 +/- 0.4 cm (p < 0.001). The ejection velocity nadir follows the septal and lateral peak velocities by 100 ms and 60 ms, respectively. The velocity nadir occurs as both walls rapidly decelerate to their premature termination: septal deceleration 79 +/- 35 cm/s2 vs. 48 +/- 21 cm/s2 (p < 0.001). With medical abolition of obstruction the MSD disappears and the duration and length of contraction normalizes.
CONCLUSIONS: These data indicate that the MSD is caused by premature termination of LV segmental shortening and is a manifestation of systolic dysfunction.

Entities:  

Mesh:

Year:  2007        PMID: 17367665     DOI: 10.1016/j.jacc.2006.10.070

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  5 in total

Review 1.  Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy.

Authors:  Julian O M Ormerod; Michael P Frenneaux; Mark V Sherrid
Journal:  Nat Rev Cardiol       Date:  2016-07-14       Impact factor: 32.419

2.  Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study.

Authors:  Raffaele Coppini; Cecilia Ferrantini; Josè Manuel Pioner; Lorenzo Santini; Zhinuo J Wang; Chiara Palandri; Marina Scardigli; Giulia Vitale; Leonardo Sacconi; Pierluigi Stefàno; Laura Flink; Katherine Riedy; Francesco Saverio Pavone; Elisabetta Cerbai; Corrado Poggesi; Alessandro Mugelli; Alfonso Bueno-Orovio; Iacopo Olivotto; Mark V Sherrid
Journal:  JACC Basic Transl Sci       Date:  2019-10-09

3.  Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy.

Authors:  Mark V Sherrid; Daniel G Swistel; Iacopo Olivotto; Maurizio Pieroni; Omar Wever-Pinzon; Katherine Riedy; Richard G Bach; Mustafa Husaini; Sharon Cresci; Alex Reyentovich; Daniele Massera; Martin S Maron; Barry J Maron; Bette Kim
Journal:  J Am Heart Assoc       Date:  2021-10-12       Impact factor: 5.501

4.  Echocardiographic predictors of severe heart failure symptoms in hypertrophic cardiomyopathy patients with sinus rhythm.

Authors:  Fatih Bayrak; Gokhan Kahveci; Muzaffer Degertekin; Bulent Mutlu
Journal:  Trials       Date:  2008-02-29       Impact factor: 2.279

Review 5.  Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice.

Authors:  Mark V Sherrid
Journal:  Curr Cardiol Rev       Date:  2016
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.